ACE2 and infection: This finding has led to ongoing trials to assess whether administration of recombinant ACE2 may address infection‐related deficiencies in lung barrier protective ACE2‐derived Ang 1‐7 generation from angiotensin II in addition to its potential action as a decoy preventing viral entry into cells (Sriram & Insel, 2020).